Nisa LeungManaging Partner at Qiming Ventures
Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments.
She sits on board of Gan & Lee (SHSE:603087), Zai Lab (NASDAQ: ZLAB), Venus MedTech (HKSE: 2500), Nurotron, CanSino Biologics (HKSE: 6185), New Horizon Bio, Berry Oncology among others. Her other investments include Aeonmed, Berry Genomics (SZSE: 000710), CITIC Pharmaceuticals (acquired by Shanghai Pharma HKSE: 2607), CrownBio (acquired by JSR), Novast, Origene (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, MEDx, Cure Genetics, SinoCell Tech(SHSE:688520), Schrödinger (NASDAQ: SDGR) and Jacobio among others.
Nisa was recognized by Forbes Global 100 VC Midas List in 2019 and 2020.
She is visiting lecturer at Harvard Law School and member of Stanford Graduate School of Business Advisory Council.